Verastem Oncology to report Q2 2026 financial results in conference callPUBT·2 days ago, 06:30 AMVSTM-2.10%
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Whybenzinga_article·Jul 21 at 02:52 PMRGNX-5.07%ADCT-5.74%
The Heterogeneity of Value Chains: From Synthetic Biology to Cloud AggregatorsGlobal Report·Jul 14 at 06:47 AMDDOG+1.01%TWST-2.35%
Under the Radar: The Tech, Biotech, and Defense Shifts You MissedGlobal Report·Jul 8 at 10:32 PMVSTM-2.10%TBI+0.92%
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VSTM Stock NewsStockTitan·Jul 2 at 07:30 AMVSTM-2.10%
VSTM: VS-7375 shows promising efficacy and safety in KRAS G12D-mutated cancers, advancing to Phase 2 trialsQuartr·Jun 23 at 03:12 PMVSTM-2.10%
Verastem says KRAS G12D inhibitor VS-7375 shows early activity in Phase 1/2 TARGET-D 101 trial across solid tumorsPUBT·Jun 23 at 03:01 PMVSTM-2.10%ERAS-1.19%
Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancerbenzinga_article·Jun 17 at 11:45 AMVSTM-2.10%
